Month: January 2019

Bedfont’s long-standing UK distributor, Intermedical UK, will be exhibiting their breath analysis medical products at the annual ARTP conference.

A distributor for nearly 10 years, Intermedical UK will be exhibiting the 2nd generation NObreath at the annual Association for Respiratory Technology & Physiology (ARTP) conference and can be found at Stand 25.

FeNO monitoring with the NObreath offers a quick, simple and non-invasive method of assessing airway inflammation for aiding the diagnosis and management of asthma. Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment(1) whilst also differentiating between allergic (eosinophilic) and non-allergic asthma(2), and if used daily, FeNO measurements can help to predict exacerbations and attacks(3).

New features for the NObreath includes the ability to save patient profiles on the device, Bluetooth connectivity, and SteriTouch technology for optimum infection control. The 2nd generation model also has a fresh and aesthetically pleasing design with a full-colour touchscreen. Furthermore, the NObreath comes with free patient management software allowing the equipment to synchronise with a PC, enabling reports to be generated, data to be backed up, and much more.

Livio Gagliardi, Acting Managing Director at Intermedical, said, “We’re excited to bring the NObreath to ARTP this year. It’s a great opportunity to talk about the benefits of measuring FeNO when monitoring asthma and airway inflammation – especially now it is recommended in the NICE guidance. We believe that the new NObreath will make FeNO monitoring quicker and easier for healthcare professionals and patients alike.”

This year, ARTP is taking place between 31 January and 1st February in Glasgow.

Bedfont Scientific Ltd. is exhibiting its wide range of medical devices at Arab Health 2019, including its new and improved NObreath® FeNO monitor

Breath analysis medical device manufacturer, Bedfont, will be returning to Arab Health 2019 – the largest healthcare exhibition in the Gulf Cooperation Council. They will be exhibiting their wide range of breath analysis medical devices, including the new and improved NObreath FeNO monitor.

The NObreath offers a quick, simple and non-invasive method of measuring FeNO to assess airway inflammation, aiding in the diagnosis and management of asthma. Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment(1) whilst also differentiating between allergic (eosinophilic) and non-allergic asthma(2), and if used daily, FeNO measurements can help to predict exacerbations and attacks(3).

Alongside a fresh and aesthetically pleasing design with a full colour touchscreen, new features of the 2nd generation NObreath also include the ability to save patient profiles on the device, Bluetooth connectivity, and SteriTouch technology for optimum infection control. Furthermore, the NObreath comes with free patient management software allowing the equipment to synchronise with a PC, enabling reports to be generated, data to be backed up, and much more.

Established in 1976, their other monitors include the Smokerlyzer, used for smoking cessation, and the ToxCO, used by emergency services, to screen for CO poisoning. The Gastrolyzer range aids in the detection of gastrointestinal disorders and food intolerances.

Matthew Skinner, Sales Team Manager, said, “Bedfont aims to continue improving and innovating health, and being the largest healthcare gathering in the GCC, Arab Health is the perfect place to find like-minded companies to work with and help raise awareness of the benefits of breath testing.”

This year, Arab Health is taking place between 28-31 January in Dubai and Bedfont can be found at stand C57, Hall 7.

REFERENCES

1.     Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti-Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.

2.     Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688

3.     Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation [Internet]. Taylor & Francis. 2017 [cited 21 September 2017]. Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990

Medical device manufacturer, Bedfont Scientific Ltd., appoints Dr Jafari to the advisory board for its gastrointestinal breath monitoring products

Bedfont, who has specialised in the design and manufacture of breath analysis medical devices for over 40 years, announces today that Dr Jafar Jafari will be the first appointment to its Gastrolyzer Medical Advisory Board.

Head of Upper GI Physiology at the Guy’s and St Thomas’ Foundation Trust Hospitals, Dr Jafari has an MD in Medicine, a PhD in Neurogastroenterology, and has been involved in over 100 research publications regarding gastroenterology. Notably, one of Dr Jafari’s main areas of interest is Hydrogen and C13 GI breath testing.

The Gastrolyzer range works by measuring exhaled levels of hydrogen and methane that are produced when the gut breaks down food; interpreting these gas levels can help to determine gastrointestinal disorders such as lactose intolerance, IBS (Irritable Bowel Syndrome) and more.

Jason Smith, Managing Director, says, “We are privileged to welcome Dr Jafari into our Bedfont Family and onto our Gastrolyzer Medical Advisory Board. We are very fortunate to be able to call upon his extensive knowledge and expertise in the gastrointestinal field.”

Dr Jafar Jafari, adds, “The Gastrolyzer range provides an instant, non-invasive and easy-to-use method for healthcare professionals and patients to use when investigating gut function. I am privileged to have been given this opportunity to contribute to Bedfont’s GI breath testing campaign.”